Bharat Biotech to make 700 million doses in 2021
Dr Krishna Ella, Chairman and MD Bharat Biotech said that Covaxin trials '200 per cent honest'
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
COVAXIN
Mixed reactions from healthcare experts, activists over REU for Covaxin, Covishield
Some ask for more transparency in the approval process and seek data related to vaccine trials while others say that grant of REU…
Brazilian Clinics plans deal with Bharat Biotech for five million doses of Covaxin
A team from ABCVAC will travel to India for further discussions with Bharat Biotech, as per reports
Drug activist group AIDAN raises concerns over EUA for COVAXIN
Urging the DCGI to reconsider the recommendations of the SEC in granting the REU approval to COVAXIN, it has aked the drug…
DCGI approves Covishield and Covaxin for restricted emergency use in India
DCGI’s decision comes after the Subject Expert Committee of CDSCO met on January 1-2, 2021 and recommended the grant of permission…
COVAXIN clinical trials recruit 23,000 subjects
COVAXIN has been evaluated in approximately 1000 subjects in Phase I and Phase II clinical trials, with promising safety and…
SEC recommends EUA for Covaxin from Bharat Biotech
The expert panel deliberated on Bharat Biotech’s EUA application after it submitted additional data, facts and analysis after…
Vice President Venkaiah Naidu meets Bharat Biotech CMD, discusses status of Covaxin
Naidu stressed the importance of PPPs in coming out with indigenous world-class products
Phase I clinical trial outcome shows Covaxin generates antibody, T-cell memory response
we hypothesize that BBV152 can generate antibodies that may persist for 6-12 months.
Ocugen and Bharat Biotech to Co-develop COVAXIN for US market
Ocugen will have US rights to the vaccine candidate and, in collaboration with Bharat Biotech, will be responsible for clinical…